Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Top Cited Papers
- 31 January 2010
- journal article
- review article
- Published by Elsevier BV in Antiviral Research
- Vol. 85 (1), 39-58
- https://doi.org/10.1016/j.antiviral.2009.09.014
Abstract
No abstract availableKeywords
This publication has 199 references indexed in Scilit:
- The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicAntiviral Research, 2010
- HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐EffectivenessClinical Infectious Diseases, 2009
- Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and InhibitionJournal of Molecular Biology, 2009
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Cytidine deamination induced HIV-1 drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2008
- 2′-Deoxy-4′-azido Nucleoside Analogs Are Highly Potent Inhibitors of Hepatitis C Virus Replication Despite the Lack of 2′-α-Hydroxyl GroupsOnline Journal of Public Health Informatics, 2008
- Lethal mutagenesis of HIVVirus Research, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionThe New England Journal of Medicine, 2004
- Mitochondrial Myopathy Caused by Long-Term Zidovudine TherapyThe New England Journal of Medicine, 1990